Compare Organon & Co. Common Stock (OGN) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Tenet Healthcare Corporation — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Tenet Healthcare Corporation trades at $271.76 (market cap $21.49B). The key difference: Tenet Healthcare Corporation is far larger — about 5.9× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Tenet Healthcare Corporation for 16 Days on average.
| OGN | THC | |
|---|---|---|
Market Cap | $3.62B | $21.49B |
Volume | 2,892,999 | 599,998 |
Sector | Health | Health |
52-Week High | $13.81 | $280.77 |
52-Week Low | $5.70 | $161.37 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $11.04B | $32.57B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Tenet Healthcare (THC) trades at $266.91, down 0.69% today but maintains strong technical momentum with bullish moving averages. The company demonstrates robust fundamentals with three consecutive quarterly earnings beats and impressive profitability metrics including 82.83% gross margins and 53.31% ROE. Recent news highlights continued investor interest and upcoming Q3 2026 earnings release on October 29.
THC presents a compelling investment case with attractive valuation (P/E 10.32), strong analyst support (81% buy rating), and 6.2% upside to consensus target of $283.36. Key risks include cash flow sustainability for capital return strategy and potential surgical volume pressures. The stock's combination of value pricing and growth execution supports continued upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
